Invention Grant
US09388134B2 Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
有权
含有SN-戊酰基-N - {[2' - （1H-四唑-5-基） - 联苯-4-基] - 甲基） - 缬氨酸和（2R，4S）-5-联苯-4-基-4 - （3-羧基 - 丙酰基氨基）-2-甲基 - 戊酸乙酯部分和阳离子
![Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations](/docs/US/2016-07-12/US09388134B2/abs.jpg.600x600.jpg)
- Patent Title: Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations
- Patent Title (中): 含有SN-戊酰基-N - {[2' - （1H-四唑-5-基） - 联苯-4-基] - 甲基） - 缬氨酸和（2R，4S）-5-联苯-4-基-4 - （3-羧基 - 丙酰基氨基）-2-甲基 - 戊酸乙酯部分和阳离子
-
Application No.: US14311788Application Date: 2014-06-23
-
Publication No.: US09388134B2Publication Date: 2016-07-12
- Inventor: Lili Feng , Sven Erik Godtfredsen , Paul Allen Sutton , Mahavir Prashad , Michael J. Girgis , Bin Hu , Yugang Liu , Thomas J. Blacklock , Piotr Henryk Karpinski
- Applicant: Lili Feng , Sven Erik Godtfredsen , Paul Allen Sutton , Mahavir Prashad , Michael J. Girgis , Bin Hu , Yugang Liu , Thomas J. Blacklock , Piotr Henryk Karpinski
- Applicant Address: CH Basel
- Assignee: NOVARTIS, AG
- Current Assignee: NOVARTIS, AG
- Current Assignee Address: CH Basel
- Agent David R. Kurlandsky
- Main IPC: A61K31/41
- IPC: A61K31/41 ; C07D207/50 ; A61K31/216 ; A61K45/06 ; A61K31/4422 ; A61K31/5415 ; C07C233/47 ; C07D257/04
![Compounds containing S-N-valeryl-N-{[2′-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations](/abs-image/US/2016/07/12/US09388134B2/abs.jpg.150x150.jpg)
Abstract:
A method for treatment of a cardiovascular or renal condition or disease with a specific combination, linked pro-drug or a compound of an angiotensin receptor antagonist and a NEPi.
Public/Granted literature
Information query
